Three-dimensional collagen-based scaffold model to study the microenvironment and drug-resistance mechanisms of oropharyngeal squamous cell carcinomas.
Oropharyngeal squamous cell carcinoma
biomimetic scaffold
collagen
drug-resistance
primary culture
zebrafish
Journal
Cancer biology & medicine
ISSN: 2095-3941
Titre abrégé: Cancer Biol Med
Pays: China
ID NLM: 101588850
Informations de publication
Date de publication:
27 Mar 2021
27 Mar 2021
Historique:
entrez:
27
3
2021
pubmed:
28
3
2021
medline:
28
3
2021
Statut:
aheadofprint
Résumé
Squamous cell carcinoma (SCC) represents the most common histotype of all head and neck malignancies and includes oropharyngeal squamous cell carcinoma (OSCC), a tumor associated with different clinical outcomes and linked to human papilloma virus (HPV) status. Translational research has few available We compared the phenotypic and genetic features of HPV-positive and HPV-negative OSCC cell lines cultured on common monolayer supports and on scaffolds. We also explored cancer cell adaptation to the 3D microenvironment and its impact on the efficacy of drugs tested on cell lines and primary cultures. HPV-positive and HPV-negative cell lines were successfully grown in the 3D model and displayed different collagen fiber organization. The 3D cultures induced an increased expression of markers related to epithelial-mesenchymal transition (EMT) and to matrix interactions and showed different migration behavior, as confirmed by zebrafish embryo xenografts. The expression of hypoxia-inducible factor 1α (1α) and glycolysis markers were indicative of the development of a hypoxic microenvironment inside the scaffold area. Furthermore, the 3D cultures activated drug-resistance signaling pathways in both cell lines and primary cultures. Our results suggest that collagen-based scaffolds could be a suitable model for the reproduction of the pathophysiological features of OSCCs. Moreover, 3D architecture appears capable of inducing drug-resistance processes that can be studied to better our understanding of the different clinical outcomes of HPV-positive and HPV-negative patients with OSCCs.
Identifiants
pubmed: 33772505
pii: j.issn.2095-3941.2020.0482
doi: 10.20892/j.issn.2095-3941.2020.0482
pmc: PMC8185858
doi:
pii:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2021 Cancer Biology & Medicine.
Déclaration de conflit d'intérêts
The authors declare no competing financial interests.
Références
Nature. 2013 Sep 19;501(7467):346-54
pubmed: 24048067
Front Oncol. 2020 Feb 26;10:239
pubmed: 32175281
Nucleic Acids Res. 2019 Jul 2;47(W1):W556-W560
pubmed: 31114875
Assay Drug Dev Technol. 2014 May;12(4):207-18
pubmed: 24831787
Laryngoscope Investig Otolaryngol. 2019 Aug 12;4(5):508-512
pubmed: 31637294
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Dev Dyn. 1995 Jul;203(3):253-310
pubmed: 8589427
Oncotarget. 2016 Sep 20;7(38):61690-61702
pubmed: 27557512
Biol Open. 2017 Feb 15;6(2):133-140
pubmed: 27895047
Clin Cancer Res. 2008 Aug 15;14(16):5069-80
pubmed: 18694994
Ann Transl Med. 2019 Jul;7(Suppl 3):S75
pubmed: 31576284
J Transl Med. 2017 Nov 7;15(1):229
pubmed: 29116016
Oncogenesis. 2016 Jan 25;5:e190
pubmed: 26807645
Int J Mol Sci. 2017 Jul 29;18(8):
pubmed: 28758931
Cell. 2009 Nov 25;139(5):891-906
pubmed: 19931152
Cancer Lett. 2018 Mar 28;417:174-181
pubmed: 29309816
Clin Med Insights Pathol. 2015 Dec 21;8:23-31
pubmed: 26740749
Cell Death Dis. 2019 Jul 15;10(8):540
pubmed: 31308358
Front Pharmacol. 2018 Jan 23;9:6
pubmed: 29410625
Anticancer Res. 2007 Jan-Feb;27(1A):471-5
pubmed: 17352269
Ther Adv Med Oncol. 2017 Dec;9(12):755-767
pubmed: 29449896
Science. 2011 Aug 26;333(6046):1157-60
pubmed: 21798893
Int J Mol Sci. 2018 Oct 04;19(10):
pubmed: 30287763
Sci Rep. 2019 Aug 22;9(1):12263
pubmed: 31439905
J Hematol Oncol. 2020 Jul 16;13(1):97
pubmed: 32677979
Oral Oncol. 2018 Dec;87:49-57
pubmed: 30527243
Trends Cell Biol. 2015 Apr;25(4):198-213
pubmed: 25540894
Carcinogenesis. 2013 Nov;34(11):2673-81
pubmed: 23784083
Biomed Res Int. 2014;2014:460654
pubmed: 25126561
Cancer Res. 2005 Jan 1;65(1):130-6
pubmed: 15665288
Pathology. 2020 Feb;52(2):179-191
pubmed: 31889547
Dev Cell. 2019 May 6;49(3):361-374
pubmed: 31063755
Cancer Lett. 2016 Sep 28;380(1):205-15
pubmed: 26272180
J Clin Oncol. 2015 Oct 10;33(29):3235-42
pubmed: 26351338
Int J Oncol. 2009 Jun;34(6):1593-602
pubmed: 19424577
Cell Mol Bioeng. 2017 Mar 6;10(3):223-234
pubmed: 31719861
Science. 2014 Feb 21;343(6173):885-8
pubmed: 24558160
Sensors (Basel). 2018 Sep 27;18(10):
pubmed: 30262739
Lancet. 2008 May 17;371(9625):1695-709
pubmed: 18486742
Curr Opin Cell Biol. 2010 Oct;22(5):697-706
pubmed: 20822891
Laryngoscope. 2012 Jul;122(7):1558-65
pubmed: 22532307
J Exp Clin Cancer Res. 2010 Feb 24;29:15
pubmed: 20181235
Cancer Biol Ther. 2015;16(8):1231-40
pubmed: 26046692
Eur J Cancer. 2017 Sep;82:115-127
pubmed: 28654785
Curr Cancer Drug Targets. 2013 Nov;13(9):963-972
pubmed: 24168186
Oncotarget. 2016 Aug 2;7(31):50781-50804
pubmed: 27434126
J Clin Oncol. 2013 Dec 20;31(36):4550-9
pubmed: 24248688
Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6235-40
pubmed: 21444794
Onco Targets Ther. 2016 Apr 04;9:1927-43
pubmed: 27110122
Front Bioeng Biotechnol. 2016 Feb 12;4:12
pubmed: 26904541
Int J Mol Sci. 2017 Dec 08;18(12):
pubmed: 29292724
Pharmacol Res. 2004 Aug;50(2):173-9
pubmed: 15177306
Expert Opin Drug Discov. 2019 Mar;14(3):289-301
pubmed: 30689452
Mol Med Rep. 2019 May;19(5):4101-4108
pubmed: 30942437
Crit Rev Oncol Hematol. 2019 May;137:57-83
pubmed: 31014516
J Otolaryngol Head Neck Surg. 2018 Sep 21;47(1):59
pubmed: 30241572
Oncotarget. 2016 Jun 21;7(25):38908-38926
pubmed: 26918353
BMC Cancer. 2017 Jun 20;17(1):434
pubmed: 28633655
Nature. 2011 Apr 7;472(7341):110-4
pubmed: 21389986
Cancers (Basel). 2018 Oct 10;10(10):
pubmed: 30308958
Eur J Cancer. 2005 Aug;41(12):1739-45
pubmed: 16051481
Clin Transl Radiat Oncol. 2017 Nov 04;8:4-11
pubmed: 29594236
Molecules. 2016 Dec 03;21(12):
pubmed: 27918490
Clin Sci (Lond). 2019 Mar 1;133(5):645-663
pubmed: 30782607